Chromatin Architecture Modification for Cancer Stem Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating radio- or chemotherapy-resistant cancer are ineffective in targeting cancer stem cells, which are often more primitive and undifferentiated, leading to uncontrolled proliferation and metastasis, and there is a lack of understanding in the regulatory mechanisms behind cancer cell heterogeneity.
Innovation Solution
The use of compositions and methods that modify the developmental states of cells by altering chromatin architecture, specifically targeting heterochromatin and nuclear lamin proteins like lamin A and lamin B1, to induce cancer maturation or senolysis, and reprogram cancer cells back to an embryonic-like state, using agents such as siRNA, gene therapy, and small molecule-based therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for treating cancer are used, then conventional therapies can be administered, but they are ineffective in targeting cancer stem cells leading to uncontrolled proliferation and metastasis
Solution Approach 1:
The patent applies parameter changes by modifying the developmental state of cancer cells from adult-like to embryonic-like through chromatin architecture modification. Specifically, it alters heterochromatin structure and lamin A/B1 expression patterns to revert cancer cells to a more primitive state, making them susceptible to differentiation-based therapies and eliminating the harmful proliferation and metastasis characteristics of cancer stem cells.
Solution Approach 2:
The patent inverts the conventional approach by not attempting to kill cancer stem cells directly or differentiate them to adult states, but rather reverting them to embryonic states where they naturally differentiate. This inversion transforms the treatment strategy from suppressing malignancy to harnessing natural developmental processes, thereby eliminating metastasis while maintaining treatment effectiveness.
2Reliability
If chromatin architecture is modified to revert cancer cells to embryonic state, then cancer maturation and senolysis are induced, but the complexity of therapeutic approaches increases
Solution Approach 1:
The patent segments the complex chromatin architecture modification into specific targetable elements: heterochromatin regions, lamin A/B1 proteins, and associated regulatory mechanisms. By focusing on these discrete components rather than attempting to reprogram entire genomes, the approach reduces therapeutic complexity while maintaining effective cancer stem cell targeting through differentiation induction.
Solution Approach 2:
The patent introduces chromatin architecture modifiers as intermediary agents that facilitate the transition from adult-like to embryonic-like states. These modifiers act as mediators between therapeutic intervention and the natural differentiation process, simplifying the overall therapy by leveraging existing developmental pathways rather than requiring direct manipulation of cancer cell proliferation mechanisms.
3Adaptability or versatility
If heterochromatin and lamin proteins are targeted to modify chromatin architecture, then developmental age of cells is altered, but the difficulty of detecting and measuring chromatin changes increases
Solution Approach 1:
The patent employs color changes as a detection mechanism for chromatin architecture modifications. By using fluorescent or chromogenic markers that bind to heterochromatin regions or lamin proteins, the changes in chromatin structure and cellular developmental state become visually detectable, thereby reducing the difficulty of measuring therapeutic effects without complicating the overall approach.
Data Source
AI summary
Compositions and methods are disclosed for modifying the chromatin structure of cells for therapeutic effect. More specifically, compositions and methods are disclosed to modify the relative expression of the nuclear lamins LMNA and LMNB1 to modify the regenerative potential of cells and to modify the heterogeneous states of cancer cells to improve therapeutic outcomes and thereby reduce tumor burden in diverse cancer types. The methods have application in veterinary and human medicine.